Skip to main content

Recro Pharma, Inc. (REPH)

NASDAQ: REPH · IEX Real-Time Price · USD
1.85 0.11 (6.32%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap86.24M
Revenue (ttm)64.02M
Net Income (ttm)-19.32M
Shares Out39.02M
EPS (ttm)-0.67
PE Ration/a
Forward PE18.25
Dividendn/a
Ex-Dividend Daten/a
Volume251,644
Open1.73
Previous Close1.74
Day's Range1.70 - 1.87
52-Week Range1.49 - 5.29
Beta1.18
AnalystsStrong Buy
Price Target5.50 (+197.3%)
Est. Earnings DateNov 9, 2021

About REPH

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.

IndustryPharmaceuticals
IPO DateMar 7, 2014
Employees185
Stock ExchangeNASDAQ
Ticker SymbolREPH
Full Company Profile

Financial Performance

In 2020, Recro Pharma's revenue was $66.50 million, a decrease of -32.98% compared to the previous year's $99.22 million. Losses were -$27.50 million, 47.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Recro Pharma stock is "Strong Buy." The 12-month stock price forecast is 5.50, which is an increase of 197.30% from the latest price.

Price Target
$5.50
(197.30% upside)
Analyst Consensus: Strong Buy

News

Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Sp...

New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturi...

1 day ago - GlobeNewsWire

Recro Reports Inducement Grants For New Staff

Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego

2 weeks ago - GlobeNewsWire

Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

2 weeks ago - Zacks Investment Research

Recro Signs Renewable Energy Agreement With Georgia Power

Investment in Renewable Energy Credits Represents Key Component of Company's Ongoing Environmental Sustainability Program Investment in Renewable Energy Credits Represents Key Component of Company's Ong...

1 month ago - GlobeNewsWire

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth

2 months ago - GlobeNewsWire

Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO

Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms

2 months ago - GlobeNewsWire

Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO

EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufa...

2 months ago - GlobeNewsWire

Recro Pharma: Q2 Earnings Insights

Shares of Recro Pharma (NASDAQ:REPH) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 112.00% over the past year to $0.03, which beat the ...

2 months ago - Benzinga

Recro Reports Second Quarter 2021 Financial Results

Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue

2 months ago - GlobeNewsWire

Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021

Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern

2 months ago - GlobeNewsWire

Recro Enters Development and Manufacturing Agreement With New Client

GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and ...

3 months ago - GlobeNewsWire

All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy

Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Recro Appoints Laura L. Parks, Ph.D.

Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Su...

4 months ago - GlobeNewsWire

Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings

Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboardin...

4 months ago - GlobeNewsWire

Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Addi...

Underwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million

5 months ago - GlobeNewsWire

Recro Announces Pricing of $30.0 Million Public Offering of Common Stock

EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufactur...

5 months ago - GlobeNewsWire

Recro Announces Proposed Public Offering of Common Stock

EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufactur...

5 months ago - GlobeNewsWire

Recro Reports First Quarter 2021 Financial Results

Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue

5 months ago - GlobeNewsWire

Recro to Report Financial Results for First Quarter 2021 on May 6

Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time

5 months ago - GlobeNewsWire

Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences

Additional Contract Broadens and Further Strengthens Customer Product Portfolio Additional Contract Broadens and Further Strengthens Customer Product Portfolio

6 months ago - GlobeNewsWire

Recro Reports Inducement Grants for New Staff

MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manuf...

6 months ago - GlobeNewsWire

Recro Strengthens Business Development Team to Drive Customer Growth and Diversification

Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing

6 months ago - GlobeNewsWire

Recro Reports Fourth Quarter and Year End 2020 Financial Results

Strengthened Industry-Centric Leadership

7 months ago - GlobeNewsWire

Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced

Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26 Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26

7 months ago - GlobeNewsWire